Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
Commentary|Articles|May 6, 2026
ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go
Author(s)Ashling Wahner
Fact checked by: Chris Ryan
Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
Preparations for the
Related to this article
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Breast cancer experts answer key questions on selecting, sequencing, and managing ADCs in HR-positive, HER2-positive, and triple-negative disease.
Trastuzumab deruxtecan plus pertuzumab improved systemic and intracranial outcomes in HER2-positive breast cancer with baseline brain metastases.
Advertisement
Advertisement